This editorial refers to 'Low-density lipoprotein cholesterol targeting with pitavastatin 1 ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial' † , by N. Hagiwara et al., on page 2264. On average, statins reduce LDL cholesterol levels between 40% and 60%, prompting the question of whether further reduction, beyond that achieved by high-intensity statins, would translate to further reductions in ASCVD events. The IMPROVE-IT trial 3 addressed this question in 18 144 subjects, hospitalized for acute coronary syndromes, randomized to simvastatin (40 mg) plus ezetimibe (10 mg) or simvastatin (40 mg) alone. Ezetimibe reduces absorption of cholesterol from the intestine (see Figure 1 ) by targeting the Niemann-Pick C1-like 1 protein. From a baseline LDL cholesterol level of 2.4 mmol/ L (93.8 mg/dL), the simvastatin þ ezetimibe group declined to 1.4 mmol/L (53.2 mg/dL), while the statin monotherapy groups declined to 1.8 mmol/L (69.9 mg/dL). This 24% greater reduction in LDL cholesterol with ezetimibe resulted in a 6% relative reduction in cardiovascular death, major coronary event, or non-fatal stroke [hazard ratio (HR) 0.936, 95% confidence interval (CI) 0.89-0.99].
High levels of LDL cholesterol are causally linked to the risk of developing atherosclerotic cardiovascular disease (ASCVD). Reducing LDL cholesterol levels has been demonstrated to result in a reduction in cardiovascular events, with supporting evidence from both epidemiological studies and numerous randomized clinical trials. A recent meta-analysis by the Cholesterol Treatment Trialists' Collaboration of 174 000 men and women demonstrated a relative risk reduction in major cardiovascular events of 22% in men and 16% in women with every 1.0 mmol/L (38.6 mg/dL) reduction in LDL cholesterol with a statin. 1 This meta-analysis demonstrated that for every 1% reduction in LDL cholesterol, the risk of ASCVD events was reduced by 1%. 2 On average, statins reduce LDL cholesterol levels between 40% and 60%, prompting the question of whether further reduction, beyond that achieved by high-intensity statins, would translate to further reductions in ASCVD events. The IMPROVE-IT trial 3 addressed this question in 18 144 subjects, hospitalized for acute coronary syndromes, randomized to simvastatin (40 mg) plus ezetimibe (10 mg) or simvastatin (40 mg) alone. Ezetimibe reduces absorption of cholesterol from the intestine (see Figure 1) Although the focus is on ezetimibe, it is worthwhile noting that racial differences must be considered even with respect to statins. 4 In Japanese patients, like those enrolled in HIJ-PROPER, there is evidence that a lower dose of statins achieves a comparable relative risk reduction in CVD events to the higher doses used in Western patients. 5 This may be due to differences in pharmacokinetics, but the detailed mechanism of the differences in response to statins between Asians and Western patients has not been fully elucidated. With respect to racial differences in responsiveness to ezetimibe, limited data are currently available, and pertain mostly to Whites, Blacks, and Hispanics, rather than Asians. 6 In HIJ-PROPER, 7 1734 Japanese subjects hospitalized for acute coronary syndrome were randomized to pitavastatin (1-4 mg) with or without ezetimibe (10 mg), and followed for a minimum of 36 months for all-cause death, major coronary event, or non-fatal stroke. In addition to being a much smaller study than IMPROVE-IT, the baseline LDL cholesterol level was much higher in this cohort, 3.4 mmol/L (135 mg/dL), although the relative reduction in LDL cholesterol was comparable, with a significant 23% greater reduction in the pitavastatin þ ezetimibe group compared with the statin monotherapy group (see Table 1 ). However, the 11% relative reduction in the primary endpoint (HR 0.89, 95% CI 0.76-1.04) did not reach statistical significance, though the effect size is comparable with IMPROVE-IT. However, in a post-hoc analysis stratified by baseline level of sitosterol, a marker of cholesterol absorption, subjects with higher pre-treatment sitosterol levels (> _2.2 lg/mL), derived a greater clinical benefit from ezetimibe than those with lower levels, P interaction = 0.01. Indeed, it has long been held that in such patients, the LDL cholesterol lowering of ezetimibe, generally modest, may be more substantive, thereby leading to more There are several differences between HIJ-PROPER and IMPROVE-IT that need to be considered when comparing the two studies. First, HIJ-PROPER was an open-label study, while IMPROVE-IT was a double-blind design. Secondly, the primary endpoints are not identical. The IMPROVE-IT composite endpoint included cardiovascular death, while HIJ-PROPER included all-cause death. IMPROVE-IT included coronary revascularization > _30 days after randomization, while HIJ-PROPER included ischaemia-driven coronary revascularization without any time stipulation. Thirdly, there are several potentially important differences in the study subjects. Over 50% of subjects in HIJ-PROPER presented with ST-segment elevation myocardial infarction (STEMI), compared with 28.5% in IMPROVE-IT. This difference may also partially explain the large difference in the use of percutaneous coronary intervention (PCI)-95% in HIJ-PROPER vs. 70% in IMPROVE-IT. Also, as mentioned above, baseline LDL cholesterol levels were much higher in HIJ-PROPER, as were the absolute levels of achieved LDL cholesterol. Prior MI (7.5%), prior PCI (8.5%), and prior coronary artery bypass graft (CABG; 1%) were much lower than in the subjects enrolled in IMPROVE-IT, with rates of 21, 19.8, and 9.3%, respectively.
While the rates of all-cause death and non-fatal MI were noticeably lower in HIJ-PROPER, the rates of coronary revascularization were considerably higher, and this appears to have driven the overall event rate in HIJ-PROPER, with higher 5-year rates than those reported in IMPROVE-IT at 7 years. Unfortunately, the rates reported in HIJ-PROPER were crude proportions rather than Kaplan-Meier rates, but the Kaplan-Meier rates can be inferred from their fig. 2A , allowing a rough estimate of the 5-year rate (see Table 1 ).
Overall, HIJ-PROPER reported a comparable additional, relative decline in LDL cholesterol achieved at 1 year with ezetimibe (23%), an 5% absolute difference in the rate of the primary outcome between the two arms compared with 2% in IMPROVE-IT, and a nonsignificant relative risk reduction of 11% compared with a significant 6% reduction in IMPROVE-IT. Despite this, the two point estimates are not dissimilar in overall magnitude.
Given that HIJ-PROPER enrolled 10% of the final PROVE-IT enrolment and that the study was powered to detect a 25% relative risk reduction, with 80% power, while IMPROVE-IT was powered to As estimated from the Kaplan-Meier curve, Figure 2A . detect a 9.4% relative risk reduction with 90% power, it is quite clear that HIJ-PROPER was underpowered to detect a statistically significant difference in events based on the use of ezetimibe in addition to statin. Under such circumstances, subset analyses, particularly posthoc subset analyses, must be viewed with caution and always as exploratory. With this in mind, the study did report a significant decline in the primary endpoint (HR 0.71, 95% CI 0.56-0.91) among the subgroup of patients with baseline sitosterol levels of > _2.2 lg/mL, which was not observed in those with sitosterol levels <2.2 lg/mL, P interaction 0.01. The other marker of cholesterol absorption, campesterol, trended in the same direction, with a non-statistically significantly greater effect of ezetimibe in those with higher levels of baseline campesterol, P interaction = 0.09, while there was no evidence of effect modification based on baseline level of lanthosterol, a marker of cholesterol synthesis, P interaction = 0.30. Missing, however, is a clear demonstration of whether this was actually associated with a greater reduction in LDL cholesterol when ezetimibe is used in such patients. Thus, there are multiple methodological reasons to view these finding with caution. Finally, even though the findings fit with a commonly held perspective, the utility of the markers chosen by the authors to indicate enhanced cholesterol absorption are not uniformly regarded as reliable or predictive. 8, 9 Thus, although further mechanistic studies may be warranted, predicted clinical applicability or importance may not be overwhelming. Individual response to ezetimibe can be gauged more pragmatically and more easily by merely measuring serial LDL cholesterol, after which it becomes obvious whether guideline-vetted LDL cholesterol goals and whether LDL cholesterol-related residual risk is being reduced materially. In the current era, if ezetimibe is shown to be ineffectual in individual LDL cholesterol lowering, newer, more potent agents with less variability in LDL cholesterol lowering have now been shown to be effective in lowering events in patients with ASCVD.
